Ozempic is the version of Novo Nordisk's semaglutide drug aimed at people with diabetes. Credit: K KStock/Adobe Stock
The high cost of treatment has been a limiting factor in the number of consumers who enjoy the weight-loss benefits of popular GLP-1 drugs. However, more than 9 in 10 prescriptions processed by DoseSpot in the first quarter of this year could have been filled at a lower prices, saving patients more than $10 million.
The prescription services company analyzed more than 100,000 GLP-1 prescriptions, finding that savings could have come from:
- Giving patients transparent pharmacy pricing information;
- Letting patients choose their pharmacy and dispensing option; and
- Manufacturer cost-savings programs, which accounted from the bulk of the potential savings.
The use of GLP-1 drugs is growing in popularity. Of the 1 in 8 U.S. adults who report using a GLP-1, 40% do so for weight loss rather than diabetes management. Researchers focused on manufacturer brands such as Mounjaro, Ozempic and Zepbound, and compounds were excluded. Ninety-four percent of these prescriptions had some form of commercial insurance coverage, and 6% were uninsured.
Recommended For You
DoseSpot evaluated whether each prescription was eligible for additional savings from a different pharmacy or through manufacturer cost-saving programs, and whether receiving the medication directly from a manufacturer (which often is less expensive) was an option. A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential cost savings that is easily in the billions of dollars, the company said.
One reason why these findings are significant is that a recent national survey found that one-third of American don't fill their prescriptions -- and the top reason is cost. GLP-1 adherence is especially low at just 46.3% at 180 days. Savings programs are a critical component of medication adherence, not just for onetime use but on a recurring basis. With compounded GLP-1s exiting the market, it’s especially important for patients to explore cost savings in other ways so they can continue taking weight-loss medications, DoseSpot CEO Josh Weiner said.
“Regardless of their insurance status, the vast majority of patients are still unaware of cost-saving programs,” he said. “Patients need to do their homework. A quick online search for these programs can yield significant savings. Patients also need to speak with providers about pharmacy pricing and dispensing options. Providers can access these details, but most don’t share it proactively -- you need to ask.”
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more inforrmation visit Asset & Logo Licensing.